文献速递呼吸危重症与机械通气

昂丹司琼对急性呼吸窘迫综合征患者呼吸驱动的影响

Effect of ondansetron on respiratory drive in patients with acute respiratory distress syndrome.
PubMed 文献 · Chest · 2026-09-29

本研究为单中心、单盲、非随机交叉试验,纳入9例有创机械通气的ARDS成人患者,比较静脉安慰剂与昂丹司琼(0.15 mg/kg,最大16 mg)对呼吸驱动的影响。结果显示昂丹司琼降低食管压压力-时间乘积、呼吸频率、分钟通气量和膈肌电活动峰值,伴PaCO2轻度上升和氧合改善。

要点

  • 昂丹司琼可降低ARDS机械通气患者的呼吸驱动指标。
  • 昂丹司琼不改变潮气量,但轻度升高PaCO2并改善氧合。
  • 该效应可能有助于避免深镇静或神经肌肉阻滞。

核心结论

  • 昂丹司琼可降低有创机械通气ARDS患者的呼吸驱动。

研究设计与样本

  • 单中心、单盲、非随机交叉试验,纳入9例成人ARDS患者,均接受有创机械通气>48小时且处于压力支持模式。

主要发现

  • 昂丹司琼使平均吸气食管压压力-时间乘积从108降至85 cmH2O·s·min-1,模型推导平均差为-23 cmH2O·s·min-1(95%CI [-28, -18];p<0.001)。
  • 呼吸频率下降-1.7次/分(95%CI [-2.0, -1.3]),分钟通气量下降-1.0 L/min(95%CI [-1.1, -0.8]),膈肌电活动峰值下降-2.4 μV(95%CI [-2.6, -2.2]),潮气量无显著变化。
  • PaCO2轻度上升+3.2 mmHg(95%CI [+1.4, +5.1];p<0.001),PaO2:FiO2比值改善+23(95%CI [6, 40];p=0.009)。

临床怎么用

  • 对于呼吸驱动过强的ARDS机械通气患者,昂丹司琼可能作为降低呼吸驱动的辅助药物。
  • 使用昂丹司琼后需监测PaCO2和氧合变化。

局限性

  • 样本量小(9例完成试验),为非随机、单盲、单中心设计,结果需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Acute respiratory distress syndrome (ARDS) is often accompanied by excessive respiratory effort contributing to patient-self-inflicted lung injury. Lung inflammation leads to increased stimulation and sensitization of pulmonary vagal afferent C-fibers. Stimulation of pulmonary C-fibers by serotonin increases respiratory effort through 5-HT3 receptors. Blocking these receptors could enable safer spontaneous ventilation and mitigate the need for deep sedation or neuromuscular blockade. RESEARCH QUESTION: Our objective was thus to evaluate the effect of ondansetron, a 5-HT3 antagonist, on (1) the pressure-time-product (PTP) of esophageal pressure (Peso) per minute and (2) respiratory rate, tidal volume, minute ventilation and electrical activity of the diaphragm (Edi). METHODS: We performed a single-center, single-blind, non-randomized crossover trial, including adults with ARDS (Berlin criteria), ventilated > 48 hours, on pressure-support mode. Participants underwent two consecutive phases: intravenous placebo (10 mL 0.9% saline) followed, 3 hours later, by intravenous ondansetron (0.15 mg/kg; max 16 mg). We continuously recorded airway pressure, flow, Peso, and Edi tracings, comparing respiratory parameters during each 3-hour phase using mixed effect models with participant-specific random intercepts and autoregressive-residual-correlation. RESULTS: We enrolled ten patients and could carry the experiment in nine. Ondansetron reduced parameters of respiratory drive. Mean inspiratory PTP fell from 108 to 85 cmH2O·s·min-1, yielding a model derived mean difference of -23 cmH2O·s·min-1 (95 % confidence interval (CI95%) [-28, -18]; p<0.001). Respiratory rate (-1.7 breaths/min; CI95% [-2.0, -1.3]), minute ventilation (-1.0 L/min; CI95% [-1.1, -0.8]), peak Edi (-2.4 μV; CI95% [-2.6, -2.2]) all declined, without significant changes in tidal volume. This was accompanied by a modest rise in PaCO2 from (+3.2 mmHg; CI95% [+1.4, +5.1]; p<0.001) and a significant improvement of the PaO2:FiO2 ratio by +23 (CI95% [6, 40] p = 0.009). CONCLUSIONS: Ondansetron reduces the respiratory drive in invasively mechanically ventilated patients with ARDS.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Cavayas YA, Caissy JA, St-Pierre M, et al. Effect of ondansetron on respiratory drive in patients with acute respiratory distress syndrome. Chest. 2026. PMID: 42810428. doi:10.1016/j.chest.2026.09.086

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。